首页> 美国卫生研究院文献>Molecular Therapy. Nucleic Acids >Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies
【2h】

Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

机译:寡核苷酸适体介导的血液恶性肿瘤精确治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Precision medicine has recently emerged as a promising strategy for cancer therapy because it not only specifically targets cancer cells but it also does not have adverse effects on normal cells. Oligonucleotide aptamers are a class of small molecule ligands that can specifically bind to their targets on cell surfaces with high affinity. Aptamers have great potential in precision cancer therapy due to their unique physical, chemical, and biological properties. Therefore, aptamer technology has been widely investigated for biomedical and clinical applications. This review focuses on the potential applications of aptamer technology as a new tool for precision treatment of hematological malignancies, including leukemia, lymphoma, and multiple myeloma.
机译:精密医学最近已成为一种有前途的癌症治疗策略,因为它不仅专门针对癌细胞,而且对正常细胞没有不利影响。寡核苷酸适体是一类小分子配体,可以以高亲和力特异性结合至它们在细胞表面的靶标。适体由于其独特的物理,化学和生物学特性而在精密癌症治疗中具有巨大潜力。因此,适体技术已被广泛研究用于生物医学和临床应用。这篇综述着重于适体技术作为精确治疗血液系统恶性肿瘤(包括白血病,淋巴瘤和多发性骨髓瘤)的新工具的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号